New Taipei City, Taiwan, Dec. 04, 2025 (GLOBE NEWSWIRE) -- Jyong Biotech Ltd. (Nasdaq: MENS) (the "Company" or "Jyong Biotech"), a science-driven biotechnology company based in Taiwan committed to developing and commercializing innovative and differentiated new drugs (plant-derived) mainly specializing in the treatment of urinary system diseases, with an initial focus on the markets of the U.S., the EU and Asia, today announced that it has entered into a non-binding Memorandum of Understanding (the "MOU") with a Vietnam‐based pharmaceutical distribution company headquartered in Ho Chi Minh City, to evaluate the development and commercialization of MCS‐2 in the Vietnam pharmaceutical market. 臺灣新北市，2025年12月4日（環球新聞）—— 科學驅動的生物技術公司Jyong Biotech Ltd.（納斯達克：MENS）（「公司」或「Jyong Biotech」），專注於開發和商業化創新且差異化的植物源新藥，主要致力於泌尿系統疾病的治療，並初步聚焦於美國、歐盟及亞洲市場。今天宣佈已與一家總部位於胡志明市的越南製藥分銷公司簽署了一份不具約束力的諒解備忘錄（「MOU」），以評估MCS‐2在越南製藥市場的發展與商業化潛力。 Under the terms of the MOU, Jyong Biotech and the Vietnam pharmaceutical distribution company will proceed with due diligence and discussions to determine the scope and structure of any definitive collaboration, including commercial strategy, regulatory pathway and local market execution. There can be no assurance that any definitive agreement will be reached or that any contemplated collaboration will be consummated. 根據諒解備忘錄條款，Jyong Biotech和越南製藥分銷公司將進行盡職調查和討論，以確定任何最終合作的範圍和結構，包括商業策略、監管路徑以及本地市場的執行方案。無法保證將達成任何最終協議，也無法保證計劃中的合作能夠完成。 網址 https://news.futunn.com/hk/post/65801869/jyong-biotech-expands-regional-partnerships-signs-mou-with-a-vietnam?level=2&data_ticket=1758060794923233
